Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721591 · ClinicalTrials.gov registry record
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 14
- Enrollment target
NCT00721591 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 14 participants.
The verdict
NCT00721591 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-03 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721591
The ClinicalTrials.gov registry entry for NCT00721591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00721591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721591 about?
NCT00721591 is a clinical study titled "Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy". To determine, through pharmacokinetic parameters, the ideal dosing protocol for dalteparin (a low molecular weight heparin) and unfractionated heparin for women desiring pregnancy who have evidence of an acquired (specifically, antiphospholipid syndrome) or inherited thrombophilia.
What is the current status of trial NCT00721591?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2005-03. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT00721591?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.